Kwarteng Alexander, Ahuno Samuel Terkper, Akoto Freda Osei
Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), PMB, KNUST, Kumasi, Ghana.
Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science Technology, PMB, Kumasi, Ghana.
Infect Dis Poverty. 2016 Oct 3;5(1):86. doi: 10.1186/s40249-016-0183-0.
There is compelling evidence that not only do anti-filarials significantly reduce larval forms, but that host immune responses also contribute to the clearance of filarial parasites; however, the underlying mechanisms have not been fully elucidated.
Filarial infections caused by Wuchereria bancrofti and Brugia species (lymphatic filariasis) and Onchocerca volvulus (onchocerciasis) affect almost 200 million individuals worldwide and pose major public health challenges in endemic regions. Indeed, the collective disability-adjusted life years for both infections is 3.3 million. Infections with these thread-like nematodes are chronic and, although most individuals develop a regulated state, a portion develop severe forms of pathology. Mass drug administration (MDA) programmes on endemic populations focus on reducing prevalence of people with microfilariae, the worm's offspring in the blood, to less than 1 %. Although this has been successful in some areas, studies show that MDA will be required for longer than initially conceived.
This paper highlights the mode of action of the various antifilarial treatment strategies and role of host immune response.
有确凿证据表明,抗丝虫药物不仅能显著减少幼虫形态,而且宿主免疫反应也有助于清除丝虫寄生虫;然而,其潜在机制尚未完全阐明。
由班氏吴策线虫和布鲁氏菌属(淋巴丝虫病)以及盘尾丝虫(盘尾丝虫病)引起的丝虫感染影响着全球近2亿人,并在流行地区构成重大公共卫生挑战。事实上,这两种感染的伤残调整生命年总数为330万。这些线状线虫感染是慢性的,尽管大多数个体发展为一种受调节状态,但一部分个体发展为严重的病理形式。针对流行人群的大规模药物治疗(MDA)计划侧重于将血液中蠕虫后代微丝蚴感染者的比例降低到1%以下。尽管这在一些地区取得了成功,但研究表明,MDA所需的时间将比最初设想的更长。
本文强调了各种抗丝虫治疗策略的作用方式以及宿主免疫反应的作用。